Dear colleagues,
It is my great honor and privilege to serve as the Editor-in-Chief of Brain Tumor Research and Treatment (BTRT), the official journal of the Korean Brain Tumor Society (KBTS), the Korean Society for Neuro-Oncology (KSNO), and the Korean Society for Pediatric Neuro-Oncology (KSPNO). While I am deeply honored to assume this responsibility, I also recognize the significant commitment it entails. I would like to express my sincere gratitude to all former Editors-in-Chief, members of the Editorial Board, and researchers in Korea and around the world have enabled BTRT to achieve its current success.
The history of BTRT began in 2002 with the launch of the Journal of the Korean Brain Tumor Society, the Society’s official journal. In 2013, the journal was reestablished as Brain Tumor Research and Treatment, becoming the official journal of both the Korean Brain Tumor Society and the Korean Society for Neuro-Oncology. With the subsequent participation of the Korean Society for Pediatric Neuro-Oncology as an official society, BTRT has evolved into the only comprehensive English-language journal in Korea dedicated to both adult and pediatric neuro-oncology.
Through the outstanding leadership of the first Editor-in-Chief, Professor Heon Yoo (2013–2017), the second Editor-in-Chief, Professor Jeong-Hyun Hwang (2017–2021), and the third Editor-in-Chief, Professor Ho-Shin Gwak (2021–2026), together with the unwavering efforts of the Editorial Board, BTRT was indexed in PubMed Central, PubMed, KoreaMed, KoreaMed Synapse, and the Korean Citation Index. A major milestone was achieved in 2025 when the journal was indexed in Scopus. In the 2025 Scopus metrics, BTRT achieved a CiteScore of 3.8, an SJR of 0.615, and a SNIP of 0.949. In particular, the journal ranked within the top 23% of journals in the Surgery category, while also demonstrating continued strength in the Clinical Neurology and Oncology categories, further strengthening its international reputation in the field of neuro-oncology.
Our vision is to establish BTRT as the leading neuro-oncology journal in Asia and a globally recognized international journal. To achieve this goal, we will continue to expand our international Editorial Board and actively encourage submissions from researchers around the world. We will place particular emphasis on attracting high-quality multicenter collaborative studies, authoritative review articles, clinical trials, clinical practice guidelines, and innovative basic and translational research. Furthermore, by strengthening collaborations with the Asian Society for Neuro-Oncology and other international neuro-oncology organizations, we aim to position BTRT as a leading platform for neuro-oncology research across Asia. These efforts will also support our goal of achieving inclusion in the Science Citation Index Expanded (SCIE).
As scientific publishing rapidly evolves with the advancement of artificial intelligence (AI), BTRT is committed to establishing clear principles for the responsible use of AI while further strengthening research integrity and publication ethics. We will progressively adopt AI-assisted publishing technologies and editorial support systems to enhance the fairness, efficiency, and transparency of the peer-review process, ensuring that BTRT remains at the forefront of modern scientific publishing.
Finally, I sincerely invite researchers, clinicians, and physician-scientists from around the world to join us in shaping the future of BTRT. With your continued support and valuable contributions, I am confident that BTRT will become a trusted journal, a preferred destination for high-quality research, and an influential international platform that advances the field of neuro-oncology.
